1. Home
  2. CGBD vs CSTL Comparison

CGBD vs CSTL Comparison

Compare CGBD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$11.02

Market Cap

759.8M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$25.05

Market Cap

806.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGBD
CSTL
Founded
2012
2007
Country
United States
United States
Employees
2500
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
759.8M
806.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CGBD
CSTL
Price
$11.02
$25.05
Analyst Decision
Hold
Strong Buy
Analyst Count
8
6
Target Price
$12.92
$47.17
AVG Volume (30 Days)
759.2K
260.4K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
15.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$3.74
$2.42
Revenue Next Year
$1.80
$12.69
P/E Ratio
$10.36
N/A
Revenue Growth
N/A
3.66
52 Week Low
$10.64
$14.59
52 Week High
$15.15
$44.28

Technical Indicators

Market Signals
Indicator
CGBD
CSTL
Relative Strength Index (RSI) 46.42 40.92
Support Level $10.64 $24.89
Resistance Level $11.44 $26.19
Average True Range (ATR) 0.32 0.94
MACD 0.02 0.34
Stochastic Oscillator 48.12 65.92

Price Performance

Historical Comparison
CGBD
CSTL

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: